Keyphrases
Cost-effectiveness
100%
Acyclovir
100%
Immunocompromised Patients
100%
Varicella-zoster Virus Infection
100%
Chickenpox
66%
Shingles
50%
Postherpetic Neuralgia
33%
Scotland
16%
Tayside
16%
Number of Patients
16%
Hospitalization
16%
Reportable Diseases
16%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Aciclovir
100%
Chickenpox
100%
Disseminated Herpes Zoster
50%
Health Care Cost
33%
Postherpetic Neuralgia
33%
Diseases
16%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Aciclovir
100%
Chickenpox
100%
Herpes Zoster
50%
Postherpetic Neuralgia
33%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Aciclovir
100%
Chickenpox
100%
Herpes Zoster
50%
Postherpetic Neuralgia
33%
Diseases
16%
Immunology and Microbiology
Chickenpox
100%
Herpes Zoster
60%